• 제목/요약/키워드: Drug side effects

검색결과 648건 처리시간 0.027초

4,5-Diaryl-2,2-Dimethyl-3(2Η)Furanone Derivatives as COX-2 Inhibitors-Next Generation Anti-Arthritis Candidate-

  • Shin, Song-Seok;Noh, Min-Soo;Byun, Young-Joo;Park, Jin-Kyu;Kim, Ji-Young;Lim, Kyung-Min;Ha, Jun-Yong;Kim, Jin-Kwan;Lee, Chang-Hoon
    • 한국응용약물학회:학술대회논문집
    • /
    • 한국응용약물학회 2001년도 추계학술대회 및 정기총회
    • /
    • pp.3-6
    • /
    • 2001
  • Inflammation is an outcome or an end effect of disruption of complex immunological balance. A variety of approaches to control immunological unbalance have been tried, and some of them are in practice in the clinic. Since inflammatory disorders are reflection of very complex immunological responses, it should be difficult to have such disorders under complete control. Thus, most of the drugs, being marketed and under development, possess some degrees of undesired side offsets originating from disruption of immunological balance. Steroids are excellent drugs suppressing inflammation in short term, however, long-term use of steroids would incur a serious side effect of "rebound". Another example is TNF-${\alpha}$-neutralizing agents, such as enbrel and infliximab. TNF-${\alpha}$ has been known to play a key role in the exacerbation of inflammation, and knock-out of TNF-${\alpha}$ is regarded essential to control of chronic inflammation. The TNF-${\alpha}$-neutralizing drugs in the market are regarded very efficient in the management of rheumatoid arthritis. Upon long term use, however, those drugs cause sepsis to a certain proportion of patients. It is ironical that a high plasma level of TNF-${\alpha}$ is known to be responsible for sepsis, and that the drugs scavenging TNF-${\alpha}$ cause sepsis. The above two examples illustrate well the difficulty of discovering an anti-inflammatory drug without unwanted immunological side effects. An anti-inflammatory drug would make a case in the market, as long as the drug has huge therapeutic benefits compared to its expected but unwanted immunological side effects, where cyclooxygenase-2 inhibitors are positioning. In this presentation, will be discussed general aspects of cyclooxygenase-2 inhibition in conjunction with 3(2Η)furanone derivatives, a novel class of COX-2 inhibitors.

  • PDF

정신과 영역에서 벤조다이아제핀계 약물의 사용과 문제점 (Practice Guideline of Use of Benzodiazepines in Psychiatric Field)

  • 오강섭
    • 대한불안의학회지
    • /
    • 제1권1호
    • /
    • pp.37-42
    • /
    • 2005
  • Benzodiazepines are widely used for a variety of conditions in psychiatric field. In this article, the author reviewed the indications, the effects on anxiety and sleep disorders, the side effects, the drug-drug interactions, and the tapering strategies. Benzodiazepines were relatively safe and useful for the treatment of anxiety and sleep disorders. However, used clinically, benzodiazepines can induce many adverse effects (e. g. over-sedation, cognitive impairments, paradoxical effects, dependence and withdrawal symptoms, and so on). Currently available informations about their effects on the developing fetus is controversial. For this reason, pregnant women and nursing mother should be cautioned against the use of benzodiazepines. Drug-drug interactions have to be considered in combination treatments. For the tapering issues, gradual tapering was important to prevent the withdrawal symptoms. Especially, the tapering schedules have to be individualized for the each long-term benzodiapzepine users.

  • PDF

DELTA OPIOID ANALGESICS

  • Burks, Thomas F.
    • 한국응용약물학회:학술대회논문집
    • /
    • 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
    • /
    • pp.50-62
    • /
    • 1994
  • Opium, morphine and rotated natural and synthetic opiates have been used since antiquity, and to the present, for the relief of moderate and severe pain. Morphine and pharmacologically related drugs, however, produced an array of undesired or dangerous side effect that limit their use as analgesics. Prominent among the limiting side effects are constipation, respiratory depression, release of prolactin, and liability for the production of drug dependence. It was our aim to develop, if possible, a drug or class of drugs with analgesic activity similar to that of morphine, but without the serious side effects associated with morphine. Our overall strategy was to take advantage of advancing knowledge concerning multiple types of opioid receptors, to develop ligands selective for the delta type receptors, to determine whether delta receptor agonists offer advantages over mu agonists, then to design compounds with pharmacokinetic properties compatible with practical therapeutic application. All but the last of these objectives have been realized.

  • PDF

신약개발과 안전성약리시험 가이드라인 (Drug Development and Guideline for Safety Pharmacology Studies)

  • 최기환;박인숙;임화경;오우용;왕소영;김소희;김주일;김동섭
    • 약학회지
    • /
    • 제47권2호
    • /
    • pp.104-109
    • /
    • 2003
  • The present paper reviews the notion and comparison of the Korea Food and Drug Administration(KFDA) general pharmacology and the International Conference on Harmonisation (ICH) safety pharmacology. General pharmacology or safety pharmacology is termed the study to determine the potential of a compound to induce adverse pharmacological effects. KFDA general pharmacology studies have been considered an important component in drug safety assessment and these were originally referred to those designed to examine effects other than the primary therapeutics effect of a drug candidate. The KFDA notified the Guideline for General Pharmacology in 1997. Safety pharmacology studies were focused on identifying adverse effects on physiological functions. In the ICH came into place S7A Safety Pharmacology Studies for Human Pharmaceuticals in 2001. A new chemical entity should be assessed for its side effects, initially in those physiological systems which are generally agreed to be the key systems that are essential for life; these "core system" include the central nervous system, cardiovascular system and respiratory system in safety pharmacology studies. These studies should be performed in compliance with Good Laboratory Practice (GLP).

Benzodiazepine계 약물과 그 문제점

  • 오강섭
    • 대한불안의학회:학술대회논문집
    • /
    • 대한불안의학회 2005년도 춘계학술대회
    • /
    • pp.88-103
    • /
    • 2005
  • o Rational Use of BZ - relative safe, widely useful o Hidden side effects/disastrous effects in vulnerable patients o Review tolerance, dependency, withdrawal symptoms o Consider Drug interaction o Periodic Evaluation of Risk/Benefit of BZ o Advice to patients planning a pregnancy

  • PDF

항정신병약물에 의한 부작용의 치료전략 (Treatment Strategy for Antipsychotic-Induced Side Effects)

  • 윤진상;신일선
    • 생물정신의학
    • /
    • 제5권2호
    • /
    • pp.166-174
    • /
    • 1998
  • 항정신병약물에 의한 부작용의 치료전략은 예방이 최우선이며, 그 다음이 조기발견 및 이에 대한 적절한 치료이다. 항정신병약물의 부작용을 강조하는 이유는, 약물에 대한 부정적 인상을 강화시키려는 데 있지 않고, 약물의 치료적 효과를 극대화시키려는 데 있다. 이를 위해서는 약물의 속성과 환자의 특징을 고려한 약물의 선택과 사용뿐만 아니라, 부작용에 대한 면밀한 이해와 이에 대한 치료전략을 숙지해야 한다.

  • PDF

한약을 복용한 소아에게 발생한 부작용에 대한 연구 (A Study of Side Effects from Korean Herb Medicine on Children)

  • 정선경;곡수영;유선애;이승연
    • 대한한방소아과학회지
    • /
    • 제24권3호
    • /
    • pp.33-42
    • /
    • 2010
  • Objectives: The purpose of this study is to investigate the frequency of side effects, and the range of the side effects from Korean herb medicine on children. Methods: The study has been carried out from 212 children who took Korean herb medicine in Department of Pediatrics, $\bigcirc\;\bigcirc$ Oriental Medical Hospital from September 2009 to February 2010. The study was completed through patients chart review and telephone survey. Results: 1. There were 6 side effect cases on male, and 3 side effect cases on female out of 212 children. The incidence of side effect was 4.2%. 2. The most common side effect was abdominal pain. The most common related organ was digestive organ. 3. The side effect occurred within one to three days after taking Korean herb medicine, and the symptoms were mostly disappeared after taking the Korean herb medicine into divided dose or less dose. Conclusions: The symptom of side effects on children was not as severe as other adverse drug reactions often seen in Western medication. The most common symptom was abdominal pain. Further studies are needed.

Multi-Layered Matrix Tablets with Various Tablet Designs and Release Profiles

  • Choi, Du-Hyung;Jeong, Seong-Hoon
    • Journal of Pharmaceutical Investigation
    • /
    • 제41권5호
    • /
    • pp.263-272
    • /
    • 2011
  • Tablet dosage forms have been preferred over other formulations for the oral drug administration due to their low manufacturing costs and ease of administrations, especially controlled-release applications. Controlled-release tablets are oral dosage forms from which the active pharmaceutical ingredient (API) is released over an intended or extended period of time upon ingestion. This may allow a decrease in the dosing frequency and a reduction in peak plasma concentrations and hence improves patient compliance while reducing the risk of undesirable side effects. Conventional singlelayered matrix tablets have been extensively utilized to deliver APIs into the body. However, these conventional single-layered matrix tablets present suboptimal delivery properties, such as non-linear drug delivery profiles which may cause higher side effects. Recently, a multi-layered technology has been developed to overcome or eliminate the limitations of the singlelayered tablet with more flexibility. This technology can give a good opportunity in formulating new products and help pharmaceutical companies enhancing their life cycle management. In this review, a brief overview on the multi-layered tablets is given focusing on the various tablet designs, manufacturing issues and drug release profiles.

Treatment of Drug Susceptible Pulmonary Tuberculosis

  • Shin, Hong-Joon;Kwon, Yong-Soo
    • Tuberculosis and Respiratory Diseases
    • /
    • 제78권3호
    • /
    • pp.161-167
    • /
    • 2015
  • Tuberculosis (TB) remains a major global health problem, and the incidence of TB cases has not significantly decreased over the past decade in Korea. The standard short course regimen is highly effective against TB, but requires multiple TB-specific drugs and a long treatment duration. Recent studies using late-generation fluoroquinolones and/or high-dose rifapentine-containing regimens to shorten the duration of TB treatment showed negative results. Extending the treatment duration may be considered in patients with cavitation on the initial chest radiograph and positivity in sputum culture at 2 months of treatment for preventing TB relapse. Current evidence does not support the use of fixed-dose combinations compared to separate drugs for the purpose of improving treatment outcomes. All patients receiving TB treatment should be monitored regularly for response to therapy, facilitation of treatment completion, and management of adverse drug reactions. Mild adverse effects can be managed with symptomatic therapy and changing the timing of the drug administration, but severe adverse effects require a discontinuation of the offending drugs.